- Home
- NGNE vs CHCT Comparison
NGNE vs CHCT Comparison
Compare NGNE & CHCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- CHCT
- Stock Information
- Founded
- NGNE 2003
- CHCT 2014
- Country
- NGNE United States
- CHCT United States
- Employees
- NGNE N/A
- CHCT N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- CHCT Real Estate Investment Trusts
- Sector
- NGNE Health Care
- CHCT Real Estate
- Exchange
- NGNE Nasdaq
- CHCT Nasdaq
- Market Cap
- NGNE 426.6M
- CHCT 425.5M
- IPO Year
- NGNE N/A
- CHCT 2015
- Fundamental
- Price
- NGNE $33.14
- CHCT $14.84
- Analyst Decision
- NGNE Strong Buy
- CHCT Buy
- Analyst Count
- NGNE 8
- CHCT 2
- Target Price
- NGNE $42.25
- CHCT $18.00
- AVG Volume (30 Days)
- NGNE 255.8K
- CHCT 242.8K
- Earning Date
- NGNE 11-14-2025
- CHCT 10-28-2025
- Dividend Yield
- NGNE N/A
- CHCT 12.80%
- EPS Growth
- NGNE N/A
- CHCT N/A
- EPS
- NGNE N/A
- CHCT N/A
- Revenue
- NGNE N/A
- CHCT $119,547,000.00
- Revenue This Year
- NGNE N/A
- CHCT $6.73
- Revenue Next Year
- NGNE N/A
- CHCT $6.07
- P/E Ratio
- NGNE N/A
- CHCT N/A
- Revenue Growth
- NGNE N/A
- CHCT 3.40
- 52 Week Low
- NGNE $6.88
- CHCT $13.23
- 52 Week High
- NGNE $74.49
- CHCT $20.87
- Technical
- Relative Strength Index (RSI)
- NGNE 63.63
- CHCT 57.99
- Support Level
- NGNE $30.52
- CHCT $14.18
- Resistance Level
- NGNE $32.99
- CHCT $15.26
- Average True Range (ATR)
- NGNE 3.33
- CHCT 0.41
- MACD
- NGNE -0.14
- CHCT 0.13
- Stochastic Oscillator
- NGNE 53.62
- CHCT 79.31
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.